Omeros Corporation
Let science lead the way
Let science lead the way
Omeros Corporation is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. Founded in 1994, the company operates in the industries of Biotechnology, Health Care, and Pharmaceutical from its headquarters in the United States. Omeros Corporation recently received a significant $6.69M grant investment on 10 April 2023 from the National Institute on Drug Abuse (NIDA). With its commitment to letting science lead the way, Omeros Corporation continues to show promise in the biopharmaceutical industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $6.69M | 1 |
-logo.jpg){kind=logo}
|
10 Apr 2023 |
| Post-IPO Equity | $100.05M | - | 12 Aug 2020 | |
| Post-IPO Equity | Unknown | - | 05 Dec 2019 | |
| Post-IPO Debt | $210.00M | - | 08 Nov 2018 | |
| Post-IPO Equity | $68.00M | - | 22 Aug 2017 |
No recent news or press coverage available for Omeros Corporation.
We care about your data, and we'd love to use cookies make your experience better.
